Prelude Therapeutics Market Risk Adjusted Performance
| PRLD Stock | | | USD 3.84 0.24 6.67% |
The Market Risk Adjusted Performance technical lookup provides context for Prelude Therapeutics and related instruments. Coverage depends on data availability and normalization;
Equity Screeners provides additional screening context. Prelude Therapeutics has market cap of 226.31 M, operating margin of -3.14%, ROE of -103.99%. Review
Your Equity Center for broader portfolio context. This reflects a position in Prelude Therapeutics in the portfolio view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
Our
How to Invest in Prelude Therapeutics guide provides practical guidance on trading Prelude Stock.
Prelude Therapeutics has current Market Risk Adjusted Performance of
-13.13.
MRAP | = | ER[a] + (1/BETA - 1) | X | ER[a] - RFR) |
| = | -13.13 | |
| ER[a] | = | Expected return on investing in Prelude Therapeutics |
| RFR | = | Risk Free Rate of return. Typically T-Bill Rate |
| BETA | = | Beta of the asset with market or selected benchmark. |
Prelude Therapeutics Market Risk Adjusted Performance Peers Comparison
Prelude Market Risk Adjusted Performance Relative To Other Indicators
Prelude Therapeutics is rated
below average. in market risk adjusted performance category among its top compatitors. It is currently under evaluation. in maximum drawdown category among its top compatitors .
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.